Robert Gagnon
About Robert Gagnon
Robert Gagnon is a Director at Bristol Myers Squibb in Princeton, New Jersey, with over 35 years of experience in the pharmaceutical industry, specializing in statistical analysis of biomarker data from clinical trials.
Current Role at Bristol Myers Squibb
Robert Gagnon currently serves as a Director at Bristol Myers Squibb in Princeton, New Jersey, United States. He began this role in July 2020, leveraging his extensive experience in statistical analysis of biomarker data from clinical trial samples. His responsibilities likely include overseeing statistical methodologies that inform the development of new therapies.
Previous Role at GSK in Oncology Biomarker Statistics
From 2017 to 2020, Robert Gagnon worked at GSK as Director of Oncology Biomarker Statistics in Collegeville, Pennsylvania, USA. During this three-year tenure, he focused on statistical approaches relevant to oncology biomarkers, contributing to the precision medicine initiatives within the company's oncology division.
Earlier Positions at Major Pharmaceutical Companies
Robert Gagnon has held multiple director-level roles throughout his career. He worked briefly at Novartis in East Hanover, NJ for six months in 2015. He also had a previous stint at Bristol Myers-Squibb as Director from 2015 to 2017. His prolific career includes a 30-year tenure at GSK, where he served as Director of Statistics and Programming until 2015.
Educational Background in Statistics
Robert Gagnon has a robust educational background in statistics. He earned his Doctor of Philosophy (Ph.D.) in Statistics from Temple University - Fox School of Business and Management, studying from 1994 to 2003. Prior to that, he achieved a Master's degree in Statistics from Villanova University, where he studied from 1986 to 1989. He also holds a Bachelor's Degree from the University of Maine, obtained from 1976 to 1980.
Over 35 Years in the Pharmaceutical Industry
Robert Gagnon has accumulated over 35 years of experience in the pharmaceutical industry, holding various director-level positions at major firms such as GSK, Novartis, and Bristol Myers Squibb. His tenure has been marked by substantial contributions to statistical analysis, particularly in the context of clinical trial biomarker data, underscoring his expertise and leadership in the field.